Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

Similar articles for PubMed (Select 22301505)

1.

Calcium, phosphate and the risk of cardiovascular events and all-cause mortality in a population with stable coronary heart disease.

Grandi NC, Brenner H, Hahmann H, Wüsten B, März W, Rothenbacher D, Breitling LP.

Heart. 2012 Jun;98(12):926-33. doi: 10.1136/heartjnl-2011-300806. Epub 2012 Feb 1.

PMID:
22301505
2.
3.

Secular changes in rates of coronary heart disease, fatal coronary heart disease, and out-of-hospital fatal coronary heart disease.

Levitan EB, Tanner RM, Zhao H, Muntner P, Thacker EL, Howard G, Glasser SP, Bittner V, Farkouh ME, Rosenson RS, Safford MM.

Int J Cardiol. 2014 Jun 15;174(2):436-9. doi: 10.1016/j.ijcard.2014.04.027. Epub 2014 Apr 13. No abstract available.

4.

Serum calcium levels are not associated with coronary heart disease.

Jin Y, He L, Wang Q, Chen Y, Ren X, Tang H, Song X, Ding L, Qi Q, Huang Z, Yu J, Yao Y.

Vasc Health Risk Manag. 2013;9:517-20. doi: 10.2147/VHRM.S49136. Epub 2013 Sep 3.

5.

Serum calcium and the calcium-sensing receptor polymorphism rs17251221 in relation to coronary heart disease, type 2 diabetes, cancer and mortality: the Tromsø Study.

Jorde R, Schirmer H, Njølstad I, Løchen ML, Bøgeberg Mathiesen E, Kamycheva E, Figenschau Y, Grimnes G.

Eur J Epidemiol. 2013 Jul;28(7):569-78. doi: 10.1007/s10654-013-9822-y. Epub 2013 Jul 17.

PMID:
23860708
6.

Alkaline phosphatase, serum phosphate, and incident cardiovascular disease and total mortality in older men.

Wannamethee SG, Sattar N, Papcosta O, Lennon L, Whincup PH.

Arterioscler Thromb Vasc Biol. 2013 May;33(5):1070-6. doi: 10.1161/ATVBAHA.112.300826. Epub 2013 Feb 21.

7.

Case/control studies with follow-up: Constructing the source population to estimate effects of risk factors on development, disease, and survival.

Sommerfelt H, Steinsland H, van der Merwe L, Blackwelder WC, Nasrin D, Farag TH, Kotloff KL, Levine MM, Gjessing HK.

Clin Infect Dis. 2012 Dec;55 Suppl 4:S262-70. doi: 10.1093/cid/cis802.

8.

Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study.

Siegerink B, Maas R, Vossen CY, Schwedhelm E, Koenig W, Böger R, Rothenbacher D, Brenner H, Breitling LP.

Clin Res Cardiol. 2013 Mar;102(3):193-202. doi: 10.1007/s00392-012-0515-4. Epub 2012 Oct 17.

PMID:
23073705
9.

Mortality risk of triglyceride levels in patients with coronary artery disease.

Kasai T, Miyauchi K, Yanagisawa N, Kajimoto K, Kubota N, Ogita M, Tsuboi S, Amano A, Daida H.

Heart. 2013 Jan;99(1):22-9. doi: 10.1136/heartjnl-2012-302689. Epub 2012 Sep 26.

PMID:
23014481
10.

Glycated haemoglobin and the risk of cardiovascular disease, diabetes and all-cause mortality in the Copenhagen City Heart Study.

Eskesen K, Jensen MT, Galatius S, Vestergaard H, Hildebrandt P, Marott JL, Jensen JS.

J Intern Med. 2013 Jan;273(1):94-101. doi: 10.1111/j.1365-2796.2012.02594.x. Epub 2012 Nov 1.

PMID:
23009556
11.

Response to 'Calcium, phosphate and the risk of cardiovascular events and all-cause mortality in a population with stable coronary heart disease'.

Lucock MD, Martin C, Boyd L, Naumovski N, Roach P, Yates Z, Veysey M.

Heart. 2013 Mar;99(5):349-50. doi: 10.1136/heartjnl-2012-302480. Epub 2012 Sep 4. No abstract available.

PMID:
22949485
12.

Plasma adiponectin levels in relation to prognosis in patients with angiographic coronary artery disease.

Li Q, Lu Y, Sun L, Yan J, Yan X, Fang L, Li M, Fan Z.

Metabolism. 2012 Dec;61(12):1803-8. doi: 10.1016/j.metabol.2012.06.001. Epub 2012 Jul 11.

PMID:
22789446
13.

Association of bone turnover markers with mortality in men referred to coronary angiography.

Lerchbaum E, Schwetz V, Pilz S, Grammer TB, Look M, Boehm BO, Obermayer-Pietsch B, März W.

Osteoporos Int. 2013 Apr;24(4):1321-32. doi: 10.1007/s00198-012-2076-9. Epub 2012 Jul 10.

PMID:
22776865
14.

Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study.

von Eynatten M, Breitling LP, Roos M, Baumann M, Rothenbacher D, Brenner H.

Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2327-35. doi: 10.1161/ATVBAHA.112.248609. Epub 2012 Jun 7.

15.

Smoking, F2RL3 methylation, and prognosis in stable coronary heart disease.

Breitling LP, Salzmann K, Rothenbacher D, Burwinkel B, Brenner H.

Eur Heart J. 2012 Nov;33(22):2841-8. doi: 10.1093/eurheartj/ehs091. Epub 2012 Apr 17.

16.

Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.

Gallego P, Roldán V, Torregrosa JM, Gálvez J, Valdés M, Vicente V, Marín F, Lip GY.

Circ Arrhythm Electrophysiol. 2012 Apr;5(2):312-8. doi: 10.1161/CIRCEP.111.967000. Epub 2012 Feb 7.

17.

Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure.

Plischke M, Neuhold S, Adlbrecht C, Bielesz B, Shayganfar S, Bieglmayer C, Szekeres T, Hörl WH, Strunk G, Vavken P, Pacher R, Hülsmann M.

Eur J Clin Invest. 2012 Jun;42(6):649-56. doi: 10.1111/j.1365-2362.2011.02631.x. Epub 2011 Dec 13.

PMID:
22150123
18.

Type II secretory phospholipase A2 and prognosis in patients with stable coronary heart disease: mendelian randomization study.

Breitling LP, Koenig W, Fischer M, Mallat Z, Hengstenberg C, Rothenbacher D, Brenner H.

PLoS One. 2011;6(7):e22318. doi: 10.1371/journal.pone.0022318. Epub 2011 Jul 22.

19.

Brain natriuretic peptide between traditional and nontraditional risk factors in hemodialysis patients: analysis of cardiovascular mortality in a two-year follow-up.

Selim G, Stojceva-Taneva O, Spasovski G, Georgievska-Ismail L, Zafirovska-Ivanovska B, Gelev S, Dzekova P, Trajcevska L, Trojacanec-Piponska S, Sikole A.

Nephron Clin Pract. 2011;119(2):c162-70. doi: 10.1159/000327615. Epub 2011 Jul 8.

PMID:
21757955
20.

Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.

Berger JS, Bhatt DL, Steg PG, Steinhubl SR, Montalescot G, Shao M, Hacke W, Fox KA, Berger PB, Topol EJ, Lincoff AM.

Am Heart J. 2011 Jul;162(1):98-105.e1. doi: 10.1016/j.ahj.2011.04.015.

PMID:
21742095
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk